6 reports of this reaction
5.6% of all OCTINOXATE reports
#3 most reported adverse reaction
BRONCHIECTASIS is the #3 most commonly reported adverse reaction for OCTINOXATE, manufactured by ALTONA COSMETICS TECHNOLOGY SANAYI VE TICARET ANONIM SIRKETI. There are 6 FDA adverse event reports linking OCTINOXATE to BRONCHIECTASIS. This represents approximately 5.6% of all 107 adverse event reports for this drug.
Patients taking OCTINOXATE who experience bronchiectasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRONCHIECTASIS is moderately reported among OCTINOXATE users, representing a notable but not dominant share of adverse events.
In addition to bronchiectasis, the following adverse reactions have been reported for OCTINOXATE:
The following drugs have also been linked to bronchiectasis in FDA adverse event reports:
BRONCHIECTASIS has been reported as an adverse event in 6 FDA reports for OCTINOXATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRONCHIECTASIS accounts for approximately 5.6% of all adverse event reports for OCTINOXATE, making it one of the most commonly reported side effect.
If you experience bronchiectasis while taking OCTINOXATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.